Novabridge Biosciences ADR
NBP3.995USD
+0.025+0.63%
Close 01/27, 16:00（ET）Quotes delayed by 15 min
460.59MMarket Cap
LossP/E TTM
More Details of Company
Novabridge Biosciences ADR Info
Ticker Symbol- -
Company name- -
IPO date- -
CEO- -
Number of employees- -
Security type- -
Fiscal year-end- -
Address- -
City- -
Stock exchange- -
Country- -
Postal code- -
Phone- -
Website- -
Ticker Symbol- -
IPO date- -
CEO- -
Company Executives of Novabridge Biosciences ADR
Name
Name/Position
Position
Shareholding
Change
Mr. Wei Fu
Mr. Wei Fu
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Chun Kwok (Alan) Au
Mr. Chun Kwok (Alan) Au
Independent Director
Independent Director
--
--
Mr. Chia-Hung (Conor) Yang
Mr. Chia-Hung (Conor) Yang
Independent Director
Independent Director
--
--
Dr. Phillip Dennis, M.D., Ph.D.
Dr. Phillip Dennis, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Xi-Yong (Sean) Fu, Ph.D.
Dr. Xi-Yong (Sean) Fu, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Robert Lenz, M.D., Ph.D.
Dr. Robert Lenz, M.D., Ph.D.
Independent Director
Independent Director
--
--
,
,
Independent Director
Independent Director
--
--
,
,
Chief Business Development Officer, Director
Chief Business Development Officer, Director
--
--
Mr. Kyler Lei
Mr. Kyler Lei
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Claire Xu
Mr. Claire Xu
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Wei Fu
Mr. Wei Fu
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Chun Kwok (Alan) Au
Mr. Chun Kwok (Alan) Au
Independent Director
Independent Director
--
--
Mr. Chia-Hung (Conor) Yang
Mr. Chia-Hung (Conor) Yang
Independent Director
Independent Director
--
--
Dr. Phillip Dennis, M.D., Ph.D.
Dr. Phillip Dennis, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Xi-Yong (Sean) Fu, Ph.D.
Dr. Xi-Yong (Sean) Fu, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Robert Lenz, M.D., Ph.D.
Dr. Robert Lenz, M.D., Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
China (Mainland)
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Jan 11
Updated: Sun, Jan 11
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Everest Medicines Ltd
13.74%
CBC Group
10.37%
T Investment Ltd
7.09%
Janus Henderson Investors
6.93%
HHLR Advisors, Ltd.
5.19%
Other
56.68%
Shareholders
Shareholders
Proportion
Everest Medicines Ltd
13.74%
CBC Group
10.37%
T Investment Ltd
7.09%
Janus Henderson Investors
6.93%
HHLR Advisors, Ltd.
5.19%
Other
56.68%
Shareholder Types
Shareholders
Proportion
Corporation
20.83%
Investment Advisor/Hedge Fund
14.77%
Private Equity
10.37%
Hedge Fund
7.26%
Investment Advisor
3.84%
Research Firm
1.69%
Individual Investor
0.56%
Venture Capital
0.26%
Sovereign Wealth Fund
0.06%
Other
40.36%
Institutional Shareholding
Updated: Wed, Jan 21
Updated: Wed, Jan 21
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q4
71
44.19M
22.87%
--
2025Q4
105
44.78M
38.84%
+10.48M
2025Q3
118
43.87M
38.07%
+959.09K
2025Q2
118
26.13M
31.79%
-13.78M
2025Q1
122
24.15M
29.39%
-18.93M
2024Q4
134
22.41M
27.40%
-20.19M
2024Q3
146
29.96M
36.94%
-20.28M
2024Q2
191
30.91M
38.11%
-23.68M
2024Q1
262
28.58M
35.04%
-19.41M
2023Q4
293
28.92M
35.46%
-21.29M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Everest Medicines Ltd
15.85M
13.74%
+15.85M
--
Aug 05, 2025
CBC Group
11.95M
10.37%
-2.64M
-18.11%
Aug 05, 2025
T Investment Ltd
8.17M
7.09%
--
--
Mar 19, 2025
Janus Henderson Investors
7.99M
6.93%
+7.99M
--
Sep 30, 2025
HHLR Advisors, Ltd.
5.98M
5.19%
--
--
Sep 30, 2025
Adage Capital Management, L.P.
3.34M
2.9%
+3.34M
--
Sep 30, 2025
Ariose Capital Management Limited
1.70M
1.48%
+1.61M
+1667.03%
Sep 30, 2025
Candriam Luxembourg S.A.
1.61M
1.4%
+2.26K
+0.14%
Nov 30, 2025
Exome Asset Management LLC
1.44M
1.25%
+1.44M
--
Sep 30, 2025
Morgan Stanley & Co. LLC
1.36M
1.18%
+1.30M
+2235.39%
Sep 30, 2025
View more
Related ETFs
Updated: Tue, Dec 9
Updated: Tue, Dec 9
Name
Proportion
ALPS Barron's 400 ETF
0.23%
SPDR S&P Emerging Markets Small Cap ETF
0.03%
SPDR S&P China ETF
0.01%
SPDR Portfolio Emerging Markets ETF
0.01%
ActivePassive International Equity ETF
0%
Avantis Emerging Markets Small Cap Equity ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Invesco Golden Dragon China ETF
0%
SPDR S&P Emerging Asia Pacific ETF
0%
ALPS Barron's 400 ETF
Proportion0.23%
SPDR S&P Emerging Markets Small Cap ETF
Proportion0.03%
SPDR S&P China ETF
Proportion0.01%
SPDR Portfolio Emerging Markets ETF
Proportion0.01%
ActivePassive International Equity ETF
Proportion0%
Avantis Emerging Markets Small Cap Equity ETF
Proportion0%
Invesco NASDAQ Future Gen 200 ETF
Proportion0%
Invesco Golden Dragon China ETF
Proportion0%
SPDR S&P Emerging Asia Pacific ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
